# Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

> **NCT04000529** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 122 (actual)

## Conditions studied

- Non-small Cell Lung Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Esophageal SCC
- Gastrointestinal Stromal Tumors
- Colorectal Cancer

## Interventions

- **DRUG:** TNO155
- **DRUG:** Spartalizumab
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT04000529
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-30
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-15
- **Target enrollment:** 122 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04000529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04000529, "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04000529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*